1	Supplementary Materials
2	
3	Effectiveness of Canadian travel restrictions in reducing burden of
4	SARS-CoV-2 variants of concern
5	
6	Angela McLaughlin ^{1,2} , Vincent Montoya ¹ , Rachel L. Miller ¹ , Canadian COVID-19 Genomics
7	Network (CanCOGeN) Consortium, Michael Worobey ³ , Jeffrey B. Joy ^{1,2,4*}
8	
9	¹ British Columbia Centre for Excellence in HIV/AIDS; British Columbia, V6Z 1Y6, Canada.
10	² Bioinformatics, University of British Columbia; British Columbia, V5T 4S6, Canada.
11	⁴ Department of Medicine University of British Columbia: British Columbia V5Z 1M9 Canada
12	Department of Medicine, Oniversity of Diffish Columbia, Diffish Columbia, V32 1113, Canada.
14 15	*Corresponding author. Email: jjoy@bccfe.ca
16	The PDF file includes:
17	
18	Materials and Methods
19 20	Eige S1 to S52
20	Tigs. S1 to S33 $Tables S1 to S3$
21	References 1-13
23	
24	
25	
26	
27	
28	
29	
30 21	
31	
32	
37	
35	
36	
37	
38	
39	
40	
41	
42	

Materials and Methods

COVID-19 incidence, mortality, and case fatality rates across Canadian provinces and territories

- Incidence, mortality, and average case fatality rate (CFR) were compared across provinces and
- territories to investigate differences in case ascertainment (Figs. S1, S2). Although the predominance of Omicron from January 2022 onwards was associated with lower CFR and testing,
- affecting the final months of the study period, our analyses assume comparable case ascertainment
- across provinces and over time.



Fig. S1. Comparison of COVID-19 cases, deaths, and case fatality rate across Canadian provinces and territories. Average daily (A) new diagnoses, (B) deaths due to COVID-19, and (C) case fatality rate over time from November 1, 2020 to March 22, 2022. Averages calculated as right-aligned 7-day rolling averages. Data from Public Health Agency of Canada (1).

- 76 Summary of variants of concern and interest studied
- 77

78 Table S1. SARS-CoV-2 variants of concern (VOCs) and interest (VOIs) prior to and

79 including early Omicron lineages, ordered by first Canadian sample date. Lambda, Theta,

80 GH/490R, and BA.3 were not included because they were sampled fewer than 100 times in

81 Canada. First global sample dates were obtained from cov-lineage.org for VOCs and outbreak.info

- 82 for VOIs; discrepancies between the two were noted. The first Canadian sample date was pulled
- 83 from clean GISAID sequences, excluding dates preceding first global sample date or incomplete
- 84 dates.

Variant	WHO	Pango	GISAID	First global	First global	First Can.	Notes
type	variant	lineage	clade	detection	sample	sample	
					date	date	
VOC	Alpha	B.1.1.7; Q.*	GRY	UK	2020-09-01	2020-11-06	outbreak.info earliest date: 2020-02-07
VOI	Zeta	P.2	GR/484K.V2	Brazil	2020-04-13	2020-11-24	n/a
VOC	Gamma	P.1	GR/501Y.V3	Brazil	2020-09-22	2020-12-04	outbreak.info earliest date: 2020-03-15
VOI	Epsilon	B.1.427; B.1.429	GH/452R.V1	California, USA	2020-04-11	2020-12-05	Dates reflect B.1.427. For B.1.429, outbreak.info earliest date: 2020-01-26
VOI	Eta	B.1.525	G/484K.V3	Nigeria; UK	2020-03-25	2020-12-14	Earliest sample from Senegal
VOC	Beta	B.1.351	GH/501Y.V2	South Africa	2020-09-01	2020-12-19	outbreak.info earliest date: 2020-02-15. First sample from Zimbabwe
VOI	Kappa	B.1.617.1	G/452R.V3	India	2020-03-03	2021-02-26	n/a
VOC	Delta	B.1.617.2; AY.*	GK	India	2021-03-01	2021-03-06	outbreak.info earliest date: 2020-03-27
VOI	Iota	B.1.526	GH/253G.V1	New York, USA	2020-01-28	2021-03-17	n/a
VOI	Mu	B.1.621	GH	Colombia	2020-12-15	2021-06-08	n/a
VOC	Omicron	BA.1; BA.2	GRA	South Africa; Botswana	2021-11-08	2021-11-04	outbreak.info earliest date: 2020-05-24. First GISAID sample, BA.1: 2021-11-02 from UK; for BA.1.1: 2021-11- 04 from Austria

85	Table S2. Summary	of inferred number	of VOC and VC	OI introductions by	March 22, 2022.
----	-------------------	--------------------	---------------	---------------------	-----------------

WHO	Pango lineage	N introduction	N sublineages	N singletons	% singletons
variant			_	_	_
Alpha	B.1.1.7; Q.*	672 (652-693)	234 (228-240)	438 (418-459)	65.2 (64.1-66.2)
Zeta	P.2	24 (24-24)	9 (9-9)	15 (15-15)	62.5 (62.5-62.5)
Gamma	P.1	197 (185-210)	38 (37-40)	159 (148-170)	80.7 (80.0-81.0)
Epsilon	B.1.427; B.1.429	76 (74-78)	27 (26-27)	49 (48-51)	65 (63.8-66.1)
Eta	B.1.525	62 (59-65)	24 (23-24)	38 (36-41)	61.6 (60.4-62.7)
Beta	B.1.351	120 (117-124)	40 (40-41)	80 (77-83)	66.7 (65.8-66.9)
Kappa	B.1.617.1	102 (101-103)	21 (20-21)	81 (81-82)	79.8 (79.3-80.3)
Delta	B.1.617.2; AY.*	1822 (1794-1850)	537 (521-553)	1285 (1253-1317)	70.5 (69.8-71.2)
Iota	B.1.526	50 (49-52)	14 (13-14)	37 (36-38)	72.6 (71.3-73.9)
Mu	B.1.621	62 (61-62)	7 (7-7)	55 (54-55)	88.5 (88.1-89.0)
Omicron	BA.1	3634 (3524-3744)	615 (596-633)	3019 (2920-3119)	83.1 (82.6-83.5)
Omicron	BA.1.1	5572 (5337-5806)	1148 (1103-1194)	4423 (4223-4624)	79.4 (78.8-79.9)
Omicron	BA.2	549 (537-565)	87 (83-92)	462 (451-473)	84 (83-85)

86 Mean and 95% confidence interval calculated using t-distribution were reported.

87

88 Estimating variant-specific cases

89 We deconvoluted cases, similarly to (3), by multiplying variant frequencies from GISAID by

90 confirmed cases over time to obtain variant-specific cases over time for all of Canada and globally

91 (Fig. S3), Canadian provinces (Fig. S4), and global regions (Fig. S6). Monthly proportional

92 contributions of geographic areas to variant cases were used to inform the subsampling

93 probabilities of sequences from either Canadian provinces (Fig. S5) or global regions (Fig. S7).

- 97 variant frequencies. (A) Average daily SARS-CoV-2 genome sequences available on GISAID
 98 after cleaning, by variant. (B) Proportional frequencies of variants among sequences available. (C)
- 99 Estimated variant cases, and (D) zoomed in below 1000 cases/day and 150,000 cases/day.

101

Fig. S4. Estimation of daily variant cases by Canadian province. (A) 7-day rolling average number of clean GISAID sequences available per day by province, colored by variant. (B) Daily average proportion of variant sequences within each province. If data was incomplete in the past 7 days, the raw count was used. For days with no sequences but with non-zero cases, variant proportions from the previous day with sequences available were carried forward. (C) Daily average new diagnoses by province. (D) Daily estimated variant-specific cases by province. Only provinces with sequences available on GISAID were shown.

110 Fig. S5. Distribution of available sequences and estimated variant cases by Canadian

111 **province.** (A) The rolling 7-day average daily and (B) monthly proportional sequences available 112 by variant colored by province. (C) The estimated daily variant-specific cases and (D) monthly

proportional contribution of each province to variant-specific cases; the latter informs the sampling

114 probability of sequences in the analysis.

Variant Deter Zeta Epsilon Beta Kappa Mu BA.1.1 Alpha Gamma Eta Delta Iota BA.1 BA.2

Fig. S6. Estimation of daily variant cases by global region. (A) Daily average clean GISAID sequences available by region, colored by variant. **(B)** Daily average proportion of sequences contributed by each variant to regional totals. If data was incomplete in the past 7 days, the raw count was used. For days with zero sequences and non-zero cases, variant proportions from the previous day with sequences available were carried forward. **(C)** Daily average new diagnoses by global region. **(D)** Daily estimated variant-specific cases by region.

123

Fig. S7. Distribution of available sequences and estimated variant cases, by global region. (A) The rolling 7-day average daily and (B) monthly proportional sequences available by variant colored by region. (C) The estimated daily variant-specific cases and (D) monthly proportional contribution of each region to variant-specific cases; the latter informs the sampling probability of sequences in the analysis.

129 Table S3. The cumulative number of estimated variant cases globally and in Canada up to

130 the day of data download March 22, 2022, relative to clean sequences available on GISAID.

131 Cumulative cases by variant were summed across global regions or Canadian provinces. Excludes

132	sequences wi	th unidentified lineage,	Theta, Lambda, a	and GH/490R.	

	Global			Canada		
Variant	Cumulative cases	Clean sequences	Sequence per case	Cumulative cases	Clean sequences	Sequence per case
Other	109,632,102	942,487	0.009	930,569	58,001	0.062
Alpha	31,471,326	1,065,890	0.034	307,680	42,596	0.138
Zeta	2,520,842	4,721	0.002	2,906	244	0.084
Gamma	15,750,416	98,939	0.006	93,762	13,488	0.144
Epsilon	3,223,780	63,369	0.02	5,591	752	0.135
Eta	445,556	6,733	0.015	19,067	1,800	0.094
Beta	4,290,486	35,606	0.008	18,326	1,414	0.077
Delta	111,501,622	3,921,060	0.035	500,617	111,192	0.222
Kappa	1,638,294	6,621	0.004	2,838	481	0.169
Iota	917,808	38,216	0.042	8,325	302	0.036
Mu	1,369,309	13,140	0.01	405	126	0.311
BA.1	65,751,679	903,272	0.014	630,408	21,242	0.034
BA.1.1	69,901,000	791,147	0.011	741,437	21,920	0.03
BA.2	42,513,492	404,349	0.01	38,009	817	0.021

133

134 <u>Subsampling strategy</u>

135 In our previous study of the first two waves of SARS-CoV-2 in Canada in 2020 and early 2021, 136 we subsampled sequences from provinces or countries with probabilities reflecting geographies' 137 monthly proportional contributions to cases (4). The more data were subsampled, the more bias 138 was reduced for previously overrepresented geographies; however, when less than 50% of the data were from Canada, our ability to identify introductions was lessened. An even split of 50% global 139 140 and 50% Canadian sequences per subsample identified the most introductions. The current analysis 141 of variant dynamics differs in a few fundamental ways. First, the available number of sequences 142 for this period of the pandemic is a magnitude larger than what was available previously. 143 Previously, we were sampling from ~60,000 Canadian sequences and ~500,000 global sequences; 144 the current analysis draws from ~300,000 Canadian sequences and >5,000,000 global sequences. 145 Another difference is the emergence of variants that are not distinguished in the case data, which 146 necessitated that we estimate the variant-specific case distribution over time (described above). 147 Geographies' monthly contributions to variant-specific cases informed sequences' sampling 148 probabilities, downweighing geographies with relatively more sequences per cases. Further, in this 149 analysis we applied temporally distributed sampling of sequences per month that mimicked the 150 distribution of variant cases (Fig. S5, S7). A simple algorithm was written in R to augment 151 sampling of sparse months where relatively few cases were identified (Fig. S8).

Fig. S8. Graphical depiction of algorithm for temporally distributed sequence subsampling.

155 Sequences subsampled mimic the distribution of variant cases over time with augmented 156 representation of sparse early months.

157

158 Subsampling improved the correlations of monthly cases to sequences among Canadian provinces

and global regions (Fig. S12, S13). For variants like Delta, where sequences were abundant but

160 differentially collected and submitted (widely different sequence per case ratio), subsampling

161 improved the correlation for Canadian provinces (Pearson's correlation coefficients: from 0.58 to

162 0.69) and global regions (from 0.47 to 0.76). Similarly, Alpha correlation improved for global

163 (0.60 to 0.90) and Canadian (0.65 to 0.77) following subsampling. The correlation between

164 monthly sequences sampled and monthly cases was improved more with temporally distributed

- 165 sampling than uniform sampling for Alpha and Delta variants.
- 166

168 Fig. S9. The relative monthly distributions of cases and sequences. Proportions of cases,

169 available sequences (seq. available), and sequences taken (seq. sampled) using the temporally

170 distributed sampling strategy for each variant in a representative subsample for (A) Canadian and

- **(B)** global datasets.

174

175 Fig. S10. Average daily and monthly proportion of sequences sampled for each Canadian

176 province for a representative subsample, grouped by variant.

- 179 Fig. S11. Average daily and monthly propotion of sequences sampled for each global region
- 180 for a representative subsample, grouped by variant.

Α

181 Fig. S12. Canadian sequence representation. The relationship between Canadian monthly 182 estimated variant cases and (A) monthly sequences available (pre-subsample) for provinces, or (B) 183 monthly sequences sampled. Relationships summarized by Pearson's correlation coefficients.

Fig. S13. Global sequence representation. The correlation between global monthly estimated
 variant cases and (A) monthly sequences available (pre-subsample) for global regions, or (B)
 monthly sequences sampled. Correlations summarized by Pearson's correlation coefficients.

- 187 Modelling travellers averted using historical travel data
- 188 Statistics Canada data on international travel arrivals was used to estimate likely travel volume in
- 189 the absence of travel restrictions for all VOCs (5). For the Delta variant, for example, we analyzed
- travel volume from India to Canada from 2018 to 2023. Average daily travellers by month revealed
- 191 seasonality (Fig. S14C), with higher-than-average travel volume from India to Canada in April
- and May, and to a lesser extent June to August, in 2018 and 2019 (pre-COVID-19), and 2022 (low
- 193 to negligible COVID-19 restrictions). Seasonality was quantified as the deviation of monthly
- 194 compared to annual average daily travellers either as the difference in the monthly and annual 195 means (diff.means) or the ratio of monthly to annual means (ratio.means) (**Fig. S15**). Across 2018,
- means (diff.means) or the ratio of monthly to annual means (ratio.means) (Fig. S15). Across 2018,
 2019 and 2022, we summarized the mean monthly deviation from the annual trend (Fig. S15C).
- 197 Expected travel in the absence of the travel ban considering seasonality was estimated as the annual
- 198 mean travel volume, adjusted by monthly diff.means or ratio.means (Fig. S16).
- 199

Fig. S14. Observed daily travellers from India to Canada (A) from January 2018 to 2023, (B)
 in 2021. (C) Bar chart of monthly mean daily travellers from India, where the black line is the
 mean daily travelers in each calendar year. Highlighted the time of year of the flight ban (April 22
 Sept 26) in adjacent years.

Fig. S15. Seasonal variation in travel volume from India summarized by deviation of monthly

- 207 compared to annual average daily travellers. (A) Difference between monthly and annual mean
 208 daily travelers ('diffmeans'). (B) Ratio between monthly and annual mean daily travelers
- 209 ('ratiomeans'). (C) The mean monthly deviation from the annual trends in 2018, 2019, and 2022.

Fig. S16. Observed (mean.trav) and expected mean daily travellers from India in the absence

212 of the COVID-19-related flight ban based on seasonality trends. Expected.diffmeans was

213 calculated as the average daily travel in 2021 plus the mean diff.mean. Expected.ratiomeans was

214 calculated as the average daily travel in 2021 times the mean ratio.mean.

215

Fig. S17. Observed daily air travel volume into Canada from all sources. (A) Daily travellers entering Canada by air, colored by Canadian residents vs. non-residents in 2021. (B) Monthly mean daily travellers from 2018 to 2022 from all sources, with black line for annual means.

219

220 With seasonal fluctuations accounted for, we next considered the epochal changes in travel volume 221 from all sources into Canada to incorporate broad changes in travel patterns due to other COVID-222 19 restrictions, which may have confounded our estimates (Fig. S17). Non-resident visitors and 223 Canadian-resident visitors daily travel volume was steadily low in 2021 until July 5, when the 224 requirement for fully vaccinated air travelers eligible to enter Canada to quarantine for 3 days in a 225 hotel and provide a test after 8 days ended (6). In September 2021, fully vaccinated foreign 226 nationals were allowed to enter Canada for non-essential reasons, corresponding to a further 227 increase in travel volume. How did observed air travel in 2021 deviate from what we expected 228 based on seasonality?

229

230 Towards this, we applied a similar strategy as conducted above for a singular source (India), but

- for all sources. We calculated the difference and ratio between expected daily travellers (resident
- and non-resident, all sources) based on seasonal trends in 2018, 2019, and 2022, and the observed

- 233 daily travellers in 2021 from all sources (Fig. S18). The monthly ratio of means is an adjustment 234 factor that takes into consideration broad travel patterns affected by other policies and willingness 235 to travel into Canada in 2021. Monthly adjustment factors were used to correct our expectations 236 of monthly travel in the absence of flight bans in India (Fig. S19). This adjusted expectation 237 considers seasonality in travel from India to Canada based on historical data, average travel from India to Canada in 2021, and broad trends in air travel from all sources in 2021. Finally, we 238 239 converted this to a daily expectation from monthly average by fitting a spline to the monthly 240 averages (Fig. S20). The number of travellers averted was calculated by comparing expected (no 241 ban) to observed (with ban).
- 242

245 Brazil (Gamma), South Africa (Beta), and Africa (Omicron) (**Fig. S21**). We estimated 724

245 Diazii (Gamma), Sodui Arrica (Deta), and Arrica (Orneron) (Fig. 521). We estimated 724

travellers from the UK were averted during the Alpha intervention; only 3 travellers from South

247 Africa were averted during the Beta intervention; 383 travellers were averted from Brazil over

both Gamma-related restriction periods; 1681 travellers from Africa were averted during the

- 249 Omicron-related travel restriction. Then, we tried to incorporate expected travel volume as a 250 confounding factor in the model between sublineage importation rate and variant cases in focal
- source.

252

Fig. S18. Seasonal variation in travel volume from all sources. (A) Mean monthly deviation from the annual trend in 2018, 2019, and 2022, summarized as the mean (across years) of the

255 difference in means or ratio of means for each month. (B) Expected daily travellers from all sources

256 versus observed (mean.trav), using difference in means or ratio of means. (C) Adjustment factor

reflecting epochal changes in overall travel was calculated for each month in 2021 as the ratio of

258 expected (ratio means) over the observed mean daily travellers.

Fig. S19. Adjusted expectations of monthly travel volume from India in the absence of flight

bans. 'Expected 1 (no ban)' is based on seasonality in India travel and 'Expected, adjusted (no
ban)' is based on seasonality and epochal travel changes from all sources.

263 264

Fig. S20. Splines convert monthly average expected travellers to daily average travellers.

Fig. S21. Expected (in the absence of restrictions) versus observed daily travellers from focal
countries affected by COVID-19 travel restrictions imposed in Canada. (A) Alpha from the
UK, (B) Beta from South Africa, (C) Gamma from Brazil, (D) Delta from India, and (E) Omicron
from southern Africa (presented for all of Africa).

276 277

Fig. S23. Alpha sublineages and descendant cases averted. (A) Estimated average daily 278 Alpha cases in the UK. (B) Linear model fit to Alpha sublineages per week from UK versus 279 average daily Alpha cases in UK prior to restrictions, subset to greater than 5000 cases. (C) Observed and predicted Alpha sublineages per week from the UK. (D) Total descendant cases 280 281 averted across all averted sublineages 282

Fig. S24. Beta sublineages and descendant cases averted. (A) Estimated average daily Beta 285 cases in South Africa. (B) Linear model fit to Beta sublineages per week from South Africa versus 286 average daily Beta cases in South Africa prior to restrictions, subset to greater than 6000 cases. 287 (C) Observed and predicted Beta sublineages per week from South Africa. (D) Total descendant 288 cases across all averted sublineages.

Fig. S25. Gamma sublineages and descendant cases averted for two interventions. (A) Estimated average daily Gamma cases in Brazil. (B) Linear model fit to Gamma sublineages per week from Brazil versus average daily Gamma cases in Brazil prior to restrictions, subset to greater than 5000 cases for the first intervention period. (C) Observed and predicted Gamma sublineages per week from Brazil. (D) Total descendant cases across all averted sublineages.

296

²⁹⁷ Fig. S26. Delta sublineages and descendant cases averted. (A) Estimated average daily Delta

cases in India. (B) Linear model fit to Delta sublineages per week from India versus average daily
 Delta cases in India prior to restrictions, subset to greater than 70,000 cases. (C) Observed and
 predicted Delta sublineages per week from India. (D) Total descendant cases averted across all
 averted sublineages.

Fig. S27. Omicron BA.1 sublineages and descendant cases averted. (A) Estimated average daily Omicron cases in South Africa and other African nations. (B) Linear model fit to Omicron sublineages per week from South Africa versus average daily Omicron cases in South Africa prior to restrictions, subset to greater than 25 cases. (C) Observed and predicted Omicron sublineages per week from South Africa. (D) Total descendant cases averted across all averted sublineages.

Fig. S28. Omicron BA.1.1 sublineages and descendant cases averted. (A) Estimated average daily Omicron cases in all of Africa. (B) Linear model fit to Omicron sublineages per week from Africa versus average daily Omicron cases in Africa prior to restrictions, subset to greater than 10 cases. (C) Observed and predicted Omicron sublineages per week, adjusted by travel, from South

315 Africa over time. Model goodness-of-fit was improved by adjusting for travel volume. (**D**) Total

316 descendant cases averted across all averted sublineages.

Supplementary Text

317318

310

309

319 <u>Timeline of Canadian COVID-19 variant era restrictions</u>

320 This timeline summarizes COVID-19 travel restrictions in Canada in the VOC era from November

321 2020 up to March 2022, including national entry requirements, epidemiological events, and

322 variant-specific travel restrictions (Fig. S29). Data was collated from a combination of resources,

including the Canadian Institute for Health Information (CIHI) (7), news releases from the

324 Government of Canada (cited throughout), and a timeline of Canada Border Services Agency 325 Border Measures (8). CIHI maintains a comprehensive list of federal, provincial and territorial

326 government interventions, announcements and other measures to reduce the spread of and improve

520 government met ventions, announcements and other measures to reduce the spread of and improve

327 the health outcomes related to COVID-19. In the main text, we focus only upon variant-specific

328 travel restrictions for Alpha, Beta, Gamma, Delta, and Omicron (Fig. 29C).

Fig. S29. Timeline of Canadian federal COVID-19 travel restrictions, including entry
 requirements and variant-specific enhanced screening or entry bans, between November 2020 and
 March 2022.

333

A synopsis of the timing of entry requirements, epidemiological events, and variant-specific
 measures in Canada towards reducing the importation and burden of VOCs.

- December 9, 2020 Health Canada approves first COVID-19 vaccine.
- December 20, 2020 January 6, 2021: Flight ban for flights arriving from the United
 Kingdom in response to the Alpha variant.
- December 24, 2020 February 22, 2021, enhanced screening for arrivals from South
 Africa in response to the Beta variant.
- As of February 15, 2021, foreign nationals arriving from the US must provide proof of a valid COVID-19 molecular test from less than 72 hours before or prior positive COVID-19 molecular test taken between 14-90 days before entry into Canada (9).
- As of February 22, 2021, all persons arriving by air or land must submit quarantine and contact information electronically on the ArriveCAN app before boarding a plane to Canada or arriving at the border with limited exceptions (9).
- On June 21, 2021 it was announced that beginning July 5, 2021, only unvaccinated travellers arriving by air would be required to stay at a government-authorized hotel for three nights, but not vaccinated travellers (6).
- Effective July 5, 2021, fully vaccinated travellers eligible to enter Canada will not be required to quarantine while they await their on-arrival test result or complete a day-8 test.
 At any time after entry to Canada, if a fully vaccinated traveller tests positive or are exposed, local public health requirements, including quarantine or isolation, apply.
- On November 19, 2021, Transport Canada announced, effective of November 30, 2021,
 the elimination of COVID-19 testing for fully vaccinated individuals departing and

- entering the country within 72 hours; expanded the list of accepted vaccines for the purpose
 of travel; valid COVID-19 tests no longer accepted as an alternative to vaccination for
 travel within Canada; new requirements for all exempt essential travellers, including the
 mandate to identify their vaccination status in ArriveCAN. Vaccination still required for
 travel within and out of Canada (10).
- January 13, 2022, effective January 15, PHAC announced Canadian truck drivers who were not fully vaccinated would not be denied entry into Canada, but unvaccinated or partially vaccinated foreign national truck drivers coming to Canada from the US by land would not be allowed entry.
- February 14, 2022, federal government invoked the Emergency Act to disperse 2022
 Freedom Convoy a protest of truckers and other anti-COVID-19 mandate supporters who
 occupied the capital for three weeks and blocked at least two major international borders.
- February 15, 2022, as of February 28, there would be easing of on-arrival testing for fully-vaccinated travellers with random testing and no quarantine required while awaiting test results (11).
- Study period end; data download date: March 22, 2022.
- April 1, 2022, fully vaccinated travellers were no longer required to provide a pre-entry COVID-19 test result to enter Canada by air, land or water; unvaccinated must continue to provide a COVID-19 test result (*12*).
- April 25, 2022, border measures eased: unvaccinated/partially vaccinated children accompanied by a fully vaccinated guardian no longer required to complete a pre-entry COVID-19 test; fully vaccinated travellers no longer need to provide a quarantine plan; fully vaccinated travellers no longer have to wear a mask in public spaces, monitor or report symptoms, quarantine if a traveller in their group shows symptoms, or maintain a list of close contacts and locations visited. Passengers still required to use ArriveCAN (*13*).
- October 1, 2022, the arriveCAN program ended and all entry requirements were dissolved.
 Vaccination, negative test, arriveCAN, or masking no longer required for all travellers
 entering Canada by air, land or marine mode.

- 384 SARS-CoV-2 VOC and VOI sublineage and singleton dynamics in Canada
- 385 Alpha (B.1.1.7)

Fig. S30. Relative contributions of global origins and Canadian destinations to Alpha variant.
sublineage importations into Canada (A) before, (B) during, and (C) after the UK flight ban.

Fig. S31. Alpha sublineages and singletons imported per week colored by global origins, in
 the context of the UK flight ban. Ribbons denote 95% confidence intervals across 10 bootstraps.

391 Zeta (P.2)

- The second variant to be identified in Canada on November 24, 2020 was Zeta (P.2, alias: B.1.1.28.2), which was closely related to the Gamma variant and initially identified in Brazil as
- 394 early as April 2020. The majority of Zeta sublineages and singletons introduced to Canada were
- imported from Brazil, with smaller contributions from the USA and Europe (Fig. S32).

402 before, during, and after the Brazil enhanced screening restriction. Flows are grouped by
 403 Pango lineage.

404

Fig. S34. Gamma sublineages and singletons introduced per week over time.

407 Epsilon (B.1.427, B.1.429)

Epsilon consists of Pango lineages, B.1.429 and B.1.427, both of which were first detected in
California, USA, with earliest sample date for B.1.427 in April 2020 and B.1.429 in January 2020
according to cov-lineages.org (Table S1). The first detection in Canada was on December 5 2020.
Our analysis suggests that Canada had 21 (20-22) B.1.429 and 6 (5-6) B.1.427 sublineages
introduced between October 9, 2020 and April 12, 2021 (Figs. S35-36). All sublineages were
inferred to have USA origins across all bootstraps.

416 Fig. S35. Epsilon sublineage flows grouped by Pango lineage.

418 Fig. S36. Epsilon sublineages and singletons per week by global region of origin.

417

420 Eta (B.1.525)

- 421 The Eta variant was first detected in the UK and Nigeria (Table S1). We estimated there were 24
- 422 (23 24) Eta sublineages imported into Canada between October 2020 and July 2021, resulting in
- 423 1762 (1759 1764) descendants sampled in Canada. There were additionally 38 (36 41) Eta
- 424 singletons introduced into Canada, accounting for 62% (60-63) of all Eta introductions.

425 Fig. S37. Eta sublineage and singleton flows.

430 Origin Destination Origin Destination Origin Destination
431 Fig. S39. Beta sublineage flows, grouped by Pango lineage, before, during, and after the enhanced screening period for South Africa.

474 Fig. S43. Relative contributions of global regions to Delta sublineages introduced to Canada

(A) before, (B) during, and (C) after the flight ban intervention. Sublineage flows are grouped 475 476 and colored by Pango lineage.

477 Fig. S44. Relative contributions of global regions to Delta singletons introduced to Canada (A) before, (B) during, and (C) after the flight ban intervention. Sublineage flows are colored 478 479 by global origin.

480

481 Fig. S45. Delta sublineages and singletons introduced per week by global origin.

489

483 *Iota (B.1.526)*

484 Iota was first identified in New York in early 2020. We inferred 14 (13 - 14) unique Iota 485 sublineages and 37 (36 - 38) singletons introduced to Canada, almost entirely from the USA and 486 primarily into Ontario.

488 Fig. S46. Iota sublineage and singleton flows.

- 492 *Mu (B.1.621)*
- 493 Mu was first identified in Colombia in December 2020 and first sampled in Canada in June 2021
- 494 (Table S1). There were at least 7 (7-7) Mu sublineages introduced to Canada and 55 (54 55)
- 495 singletons. Despite its first discovery in Colombia, 72% of Mu sublineages and 79% of singletons
- 496 were inferred to have come from the USA, with 28% of sublineages and 11% of singletons from
- 497 South America. Sequences from the USA comprised 45.1% of global sequences sampled, while
- 498 39.8% were from South America.

500 Fig S48. Mu sublineage and singleton flows into Canada.

- 502 Fig. S49. Mu sublineages and singletons imported per week into Canada.
- 503

505 Fig. S50. Relative contributions of global regions to BA.1 sublineages (A) before, (B) during,

506 **(C) and after the travel restrictions.**

Fig. S51. BA.1 sublineages and singletons introduced per week, in the context of the southern
 Africa entry ban and enhanced screening intervention.

510 Fig. S52. BA.1.1 sublineages and singletons introduced per week, in the context of the 511 southern Africa entry ban and enhanced screening intervention.

512 Fig. S53. BA.2 sublineages and singletons introduced per week, in the context of the southern

- 513 Africa entry ban and enhanced screening intervention.
- 514
- 515 References
- 516
- 517 1. Public Health Agency of Canada, "Coronavirus disease 2019 (COVID-19): Epidemiology
- 518 update" (Government of Canada, Ottawa, ON, 2021), https://health-infobase.canada.ca/covid-
- 519 19/epidemiological-summary-covid-19-cases.html?stat=num&;measure=active#a2.
- 520 2. Statistics Canada, 2021 Census Population and dwelling counts: Canada, provinces and
- 521 territories (2022), (available at
- 522 https://www150.statcan.gc.ca/t1/tbl1/en/tv.action?pid=9810000101).
- 523 3. M. D. Figgins, T. Bedford, SARS-CoV-2 variant dynamics across US states show consistent
- 524 differences in effective reproduction numbers, *Medrxiv* [Preprint] (2022)
- 525 doi:10.1101/2021.12.09.21267544.
- 4. A. McLaughlin, V. Montoya, R. L. Miller, G. J. Mordecai, C. C.-19 G. N. (CanCOGen)
- 527 Consortium, M. Worobey, A. F. Poon, J. B. Joy, Genomic epidemiology of the first two waves 528 of SARS-CoV-2 in Canada. *eLife*. **11**, e73896 (2022).
- 529 5. Statistics Canada, Leading indicator, International visitors entering or returning to Canada by 530 air, by country of residence and traveller type (2023), https://doi.org/10.25318/2410005601-eng.
- 531 6. Public Health Agency of Canada, Government of Canada's first phase to easing border
- 532 measures for travellers entering Canada (2021), https://www.canada.ca/en/public-
- 533 health/news/2021/06/government-of-canadas-first-phase-to-easing-border-measures-for-
- 534 travellers-entering-canada3.html.
- 535 7. Canadian Institute for Health Information, COVID-19 Intervention Timeline in Canada Data
- 536 Tables (2021), https://www.cihi.ca/en/covid-19-intervention-timeline-in-canada.

- 537 8. Government of Canada, Timeline CBSA Border Measures (2021),
- 538 https://www.publicsafety.gc.ca/cnt/trnsprnc/brfng-mtrls/prlmntry-bndrs/20211015/08-en.aspx.
- 539 9. Government of Canada, Current travel restrictions—Standing Committee on Health:
- 540 Emergency Situation Facing Canadians in Light of the COVID-19 Pandemic (2021),
- 541 https://www.cbsa-asfc.gc.ca/transparency-transparence/pd-dp/bbp-rpp/hesa/2021-05-
- 542 21/travrestrict-restrictvoya-eng.html.
- 543 10. Public Health Agency of Canada, Adjustments to Canada's border and travel measures
- 544 (2021), https://www.canada.ca/en/public-health/news/2021/11/adjustments-to-canadas-border-
- 545 and-travel-measures.html.
- 546 11. Public Health Agency of Canada, Government of Canada lightens border measures as part of
- 547 transition of the pandemic response (2022), https://www.canada.ca/en/public-
- 548 health/news/2022/02/government-of-canada-lightens-border-measures-as-part-of-transition-of-
- 549 the-pandemic-response.html.
- 550 12. Public Health Agency of Canada, Government of Canada will remove pre-entry test
- 551 requirements for vaccinated travellers on April 1 (2022), https://www.canada.ca/en/public-
- bealth/news/2022/03/government-of-canada-will-remove-pre-entry-test-requirement-for-fully-
- 553 vaccinated-travellers-on-april-1.html.
- 13. Public Health Agency of Canada, Government of Canada announces additional easing of
- border measures effective April 25 (2022), https://www.canada.ca/en/public-
- $\label{eq:solution} bealth/news/2022/04/government-of-canada-announces-additional-easing-of-border-measures-additional-e$
- 557 effective-april-25.html.
- 558